RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A
- PMID: 18592002
- PMCID: PMC2434205
- DOI: 10.1593/neo.08312
RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A
Abstract
More than half of all colorectal carcinomas are known to exhibit an activated mitogen-activated protein kinase pathway. The NF1 gene, a negative regulator of KRAS, has not previously been examined in a series of colorectal cancer. In the present study, primary colorectal carcinomas stratified according to microsatellite instability status were analyzed. The whole coding region of NF1 was analyzed for mutations using denaturing high-performance liquid chromatography and sequencing, and the copy number alterations of NF1 were examined using multiple ligation-dependent probe amplification and real-time polymerase chain reaction. The mutational hot spots in KRAS and BRAF were sequenced, and promoter hypermethylation status of RASSF1A was assessed with a methylation-specific polymerase chain reaction. One sample had two missense mutations in NF1, whereas nine additional tumors had intronic mutations likely to affect exon splicing. Interestingly, 8 of these 10 tumors were microsatellite-unstable. Four other tumors showed a duplication of NF1. Mutations in KRAS and BRAF were mutually exclusive and were present at 40% and 22%, respectively. RASSF1A was hypermethylated in 31% of the samples. We show that the RAS signaling network is extensively dysregulated in colorectal carcinomas, because more than 70% of the tumors had an alteration in one or more of the four examined components.
Figures


Similar articles
-
Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.Oncogene. 2005 Nov 17;24(51):7630-4. doi: 10.1038/sj.onc.1208906. Oncogene. 2005. PMID: 16007118
-
Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.Int J Cancer. 2004 Apr 10;109(3):377-84. doi: 10.1002/ijc.11722. Int J Cancer. 2004. PMID: 14961576
-
Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers.J Exp Clin Cancer Res. 2006 Jun;25(2):235-42. J Exp Clin Cancer Res. 2006. PMID: 16918136
-
Frequent hypermethylation of RASSF1A in early flat-type colorectal tumors.Oncogene. 2004 Nov 25;23(55):8900-7. doi: 10.1038/sj.onc.1207993. Oncogene. 2004. PMID: 15480433
-
Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.Gut. 2009 Sep;58(9):1234-41. doi: 10.1136/gut.2008.159137. Epub 2009 May 26. Gut. 2009. PMID: 19474002
Cited by
-
Neoplasia: the second decade.Neoplasia. 2008 Dec;10(12):1314-24. doi: 10.1593/neo.81372. Neoplasia. 2008. PMID: 19048110 Free PMC article.
-
Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?Anticancer Agents Med Chem. 2012 Feb;12(2):163-71. doi: 10.2174/187152012799014968. Anticancer Agents Med Chem. 2012. PMID: 22043994 Free PMC article. Review.
-
JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype.Neoplasia. 2009 Jan;11(1):87-95. doi: 10.1593/neo.81188. Neoplasia. 2009. PMID: 19107235 Free PMC article.
-
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer.Br J Cancer. 2011 Mar 1;104(5):856-62. doi: 10.1038/bjc.2011.19. Epub 2011 Feb 1. Br J Cancer. 2011. PMID: 21285991 Free PMC article.
-
Loss of RASSF1A expression in colorectal cancer and its association with K-ras status.Biomed Res Int. 2013;2013:976765. doi: 10.1155/2013/976765. Epub 2013 Jun 22. Biomed Res Int. 2013. PMID: 23865079 Free PMC article.
References
-
- Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005;6:322–327. - PubMed
-
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. - PubMed
-
- Santos E, Martin-Zanca D, Reddy EP, Pierotti MA, Della PG, Barbacid M. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science. 1984;223:661–664. - PubMed
-
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. - PubMed
-
- Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001;104:593–604. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous